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BACKGROUND: Hypertrophic cardiomyopathy is the leading cause of sudden 
cardiac death (SCD) in children and young adults. Our objective was to 
develop and validate a SCD risk prediction model in pediatric hypertrophic 
cardiomyopathy to guide SCD prevention strategies.
METHODS: In an international multicenter observational cohort study, 
phenotype-positive patients with isolated hypertrophic cardiomyopathy <18 
years of age at diagnosis were eligible. The primary outcome variable was the 
time from diagnosis to a composite of SCD events at 5-year follow-up: SCD, 
resuscitated sudden cardiac arrest, and aborted SCD, that is, appropriate shock 
following primary prevention implantable cardioverter defibrillators. Competing 
risk models with cause-specific hazard regression were used to identify and 
quantify clinical and genetic factors associated with SCD. The cause-specific 
regression model was implemented using boosting, and tuned with 10 repeated 
4-fold cross-validations. The final model was fitted using all data with the tuned 
hyperparameter value that maximizes the c-statistic, and its performance was 
characterized by using the c-statistic for competing risk models. The final model 
was validated in an independent external cohort (SHaRe [Sarcomeric Human 
Cardiomyopathy Registry], n=285).
RESULTS: Overall, 572 patients met eligibility criteria with 2855 patient-years of 
follow-up. The 5-year cumulative proportion of SCD events was 9.1% (14 SCD, 25 
resuscitated sudden cardiac arrests, and 14 aborted SCD). Risk predictors included 
age at diagnosis, documented nonsustained ventricular tachycardia, unexplained 
syncope, septal diameter z-score, left ventricular posterior wall diameter z score, 
left atrial diameter z score, peak left ventricular outflow tract gradient, and 
presence of a pathogenic variant. Unlike in adults, left ventricular outflow tract 
gradient had an inverse association, and family history of SCD had no association 
with SCD. Clinical and clinical/genetic models were developed to predict 5-year 
freedom from SCD. Both models adequately discriminated between patients with 
and without SCD events with a c-statistic of 0.75 and 0.76, respectively, and 
demonstrated good agreement between predicted and observed events in the 
primary and validation cohorts (validation c-statistic 0.71 and 0.72, respectively).
CONCLUSION: Our study provides a validated SCD risk prediction model with 
>70% prediction accuracy and incorporates risk factors that are unique to 
pediatric hypertrophic cardiomyopathy. An individualized risk prediction model 
has the potential to improve the application of clinical practice guidelines and 
shared decision making for implantable cardioverter defibrillator insertion.
REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: 
NCT0403679. 
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Hypertrophic cardiomyopathy (HCM) is the most common form of cardiomyopathy affecting at least 1 in 500 individuals and is a leading cause 
of sudden cardiac death (SCD) in adolescents and 
young adults.1–3 SCD is related primarily to the occur-
rence of significant arrhythmias including ventricular 
fibrillation or sustained ventricular tachycardia (VT).4,5 
Implantable cardioverter defibrillators (ICDs) can pre-
vent SCD by detecting and terminating sustained VT or 
ventricular fibrillation. They are offered to patients who 
have survived documented near-death events, known 
as secondary prevention ICD, or prophylactically to 
those who have not yet experienced an event but who 
are deemed at high risk for an event, known as primary 
prevention ICD. Despite the availability of this life-sav-
ing intervention, the lack of precision in predicting SCD 
risk hampers timely ICDs in at-risk individuals, resulting 
in tragic but preventable deaths. Risk is often overesti-
mated in lower-risk patients, resulting in potentially un-
warranted ICD implantation.6–10 This can have negative 
medical, psychological, and financial consequences, 
because ICD therapy is associated with a 20% com-
plication rate, and an 11% inappropriate shock rate in 
children (higher with epicardial ICD placement).8,11–14
Published clinical practice guidelines define high risk 
for SCD by the presence of ≥1 clinical risk factors.4,15,16 
However, clinical practice recommendations are inconsis-
tently and variably applied in practice likely because ICD 
decision making is driven by a subjective perception of 
risk with considerable variability in risk tolerance among 
practitioners and patients, and a more conservative up-
take because of a higher complication rate of ICDs in 
pediatric than in adult patients.8,16,17 In recent years, the 
European Society of Cardiology developed and validated 
a web-based tool that incorporates evidence-based clini-
cal risk factors into an algorithm to predict 5-year sud-
den death risk in adult patients >16 years of age, but 
does not apply to children.18–22 This model did not include 
other potential risk factors like the genetic etiology of 
HCM that can influence the risk of SCD.15,23,24 In addition, 
studies have shown that the European Society of Cardiol-
ogy 2014 risk prediction model had a lower sensitivity in 
high-risk populations. As a result, the European Society of 
Cardiology 2014 model frequently misidentified patients 
who experienced a SCD event as low risk.20,25–27 A recent 
study from the United Kingdom reported on the perfor-
mance of a SCD risk prediction model for pediatric HCM 
developed using 5 preselected clinical variables with a c-
statistic of 0.69, but this model has not been externally 
validated.28 The lack of evidence-based decision support 
for SCD risk prediction in childhood HCM has been iden-
tified as an important practice gap.
The purpose of our study was to develop and vali-
date a risk prediction model for SCD in pediatric HCM 
using evidence-based risk factors to assist physicians 
and patients in shared decision making for primary pre-
vention ICD implantation.
METHODS
The data that support the findings of this study are available 
from the corresponding author on reasonable request.
Study Cohort and Participating Centers
This was a multicenter retrospective observational cohort study 
of pediatric patients with clinically diagnosed childhood-onset 
HCM. Eligibility criteria included clinical diagnosis of HCM, 
LV posterior wall or septal thickness z score ≥2,29,30 age <18 
years at the time of diagnosis, absence of a SCD event before 
diagnosis, and at least 1 follow-up assessment after diagno-
sis. Genotype-positive subjects who did not have echocardio-
graphic evidence of LV hypertrophy and patients with known or 
suspected secondary causes of HCM, ie, clinical syndromes like 
RASopathies (Noonan syndrome, Noonan syndrome with mul-
tiple lentigines, Costello syndrome, Cardiofaciocutaneous syn-
drome, and Neurofibromatosis type 1), endocrine, metabolic, 
mitochondrial, or neuromuscular disorders, hypertension, and 
Clinical Perspective
What Is New?
• Patients with pediatric hypertrophic cardiomyopa-
thy had a high 5-year cumulative sudden cardiac 
death risk of 9.1%.
• A large international cohort analysis identified a 
positive association of unexplained syncope and 
nonsustained ventricular tachycardia, a nonlinear 
association of age, septal and left ventricular pos-
terior wall thickness and left atrial diameter, and no 
association of left ventricular outflow tract gradient 
with sudden cardiac death risk (inverse association 
with a gradient ≥100 mm Hg).
• An integrated model that incorporated all age-
appropriate risk factors provided individualized 
scores for 5-year sudden cardiac death risk and is 
the first prediction model to be externally validated 
in an independent cohort with high performance 
accuracy.
What Are the Clinical Implications?
• The decision for primary prevention implantable 
cardioverter defibrillators in patients with pediatric 
hypertrophic cardiomyopathy should not be based 
on a single risk factor, but should incorporate all 
age-appropriate, evidence-based risk factors.
• The PRIMACY (Precision Medicine for Cardiomy-
opathy) sudden cardiac death risk prediction model 
can be implemented within hospital electronic 
health systems as a point-of-care tool to help guide 
physicians in shared decision making with patients 
with childhood-onset hypertrophic cardiomyopathy 
and families regarding primary prevention implant-
able cardioverter defibrillator.
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structural heart defects were excluded. Age at diagnosis was 
defined as the age at echocardiogram at which the diagno-
sis of HCM was made. All centers used the same echocardio-
graphic criteria for the diagnosis of hypertrophy.
The primary cohort included patients from 11 sites par-
ticipating in the PRIMaCY study (Precision Medicine for 
Cardiomyopathy), an international registry of patients with pedi-
atric HCM launched in 2017. These included 4 Canadian, 6 US, 
and 1 Australian site. For model validation in an independent 
cohort, we used data from patients with childhood-onset HCM 
from SHARE (the Sarcomeric Human Cardiomyopathy Registry), 
a registry of 15 international centers capturing longitudinal clini-
cal data on deidentified patients with HCM.23 For the 4 sites that 
contributed data to both registries, any overlapping patients 
were excluded from the validation cohort. Clinical, genetic, 
and outcomes data were collected from the medical records 
in all eligible patients from the time of diagnosis to last follow-
up. Echocardiographic data were collected at initial diagnosis 
and at last follow-up. For patients with major cardiac events 
(death, transplant, SCD), data were captured before the event. 
Echocardiographic data were collected from clinical reports, and, 
where feasible, missing data were collected through a re-review 
of the echocardiograms at local sites by the research team. SCD 
events were reviewed by site investigators to confirm the cause 
of death. The research protocol was approved by the institu-
tional research ethics boards at all sites and waiver of consent 
was obtained for this retrospective study. All patient data were 
deidentified for data sharing and analyses. The corresponding 
author had full access to all the data in the study and takes 
responsibility for its integrity and the data analysis.
Selection of Predictor Variables
To generate a risk prediction model, candidate risk factors 
based on the American College of Cardiology Foundation/
American Heart Association published clinical practice guide-
lines were assessed.4 Echocardiographic measurements of wall 
thickness and chamber sizes were converted to z scores using 
the Boston z score calculator.29,30 The risk factors included age 
at diagnosis, family history of SCD, history of recent unex-
plained syncope within 6 months before the diagnosis, docu-
mented nonsustained VT (defined as ≥3 beats at ≥120 bpm 
on ambulatory ECG), interventricular septal diameter (IVSD) z 
score, LV posterior wall diameter (LVPWD) z score, left atrial 
(LA) diameter z score, and peak resting LV outflow tract (LVOT) 
gradient on echocardiography. Genetic results from clinical 
testing were captured from medical records and, through 
research sequencing, in a subset of patients. Data included 
affected gene and variant pathogenicity, that is, pathogenic/
likely pathogenic, variant of uncertain significance or benign.31 
Variant classification was reconfirmed using American College 
of Medical Genetics criteria at the core site. Patients harbor-
ing pathogenic/likely pathogenic variants in cardiomyopathy 
genes were considered genotype positive (Table I in the Data 
Supplement). Ethnicity information was only available in 102 
patients and therefore was not included in the analysis.
Statistical Analysis
All statistical analyses were performed using R version 
3.4.1 with survival, multiple imputation by chained equa-
tions, mboost, riskRegression, and mlr packages. Clinical 
characteristics were summarized using descriptive statistics. 
Continuous variables were summarized using median and 
interquartile range, whereas categorical variables were sum-
marized using frequencies and proportions. The primary 
outcome was time to an SCD event during 5-year follow-up 
defined as a composite outcome of SCD, resuscitated sud-
den cardiac arrest (including sustained VT/ventricular fibrilla-
tion), and aborted SCD events, that is, appropriate shock in 
a patient with a primary prevention ICD. Event-free survival 
was estimated by using the Kaplan-Meier method as was the 
cumulative proportion of SCD events over time.
Model Development and Performance 
Assessment
General Modeling Approach 
To generate a risk prediction model, the relative contribu-
tion of the clinical and genetic predictors was quantified by 
using a competing risk model for SCD events with non-SCD 
death as the competing risk. This analysis was implemented 
by using cause-specific regression. To ensure that the quan-
tification was pertinent to the clinical context, patients were 
administratively censored at 5 years from first evaluation. 
Two models were considered: a clinical-only model and a 
clinical/genetic model that included genotype status of the 
patient. Patients harboring a pathogenic/likely pathogenic 
causal variant on genetic testing, that is, genotype-positive 
patients, were compared with patients without a causal vari-
ant on testing. We applied a model-boosting algorithm to 
the cause-specific hazard regression to identify and quantify 
the association between the candidate risk factors and the 
composite outcome. For continuous risk factors, the asso-
ciations were modeled without the assumption of linearity 
using penalized b-splines. The estimated nonlinear associa-
tions were summarized graphically. On the fitting of the 2 
boosted models, we then obtained the linear predictors and 
baseline hazard for the SCD events. This cause-specific haz-
ard regression implementation for competing risk data has 
been previously described.32
Model Tuning 
To tune the boosting model, we applied 10 repeated 4-fold 
cross-validations to determine the hyperparameter of the 
boosting model. In this exercise, we considered a small learn-
ing rate (step size) of 0.01 and a large number of steps. 
Within each cross-validation iteration, we imputed the miss-
ing values by using multiple imputation by chained equations 
before training the model. This scheme of nested imputations 
was demonstrated in a similar prognostic study setting.33,34 
The plausibility of missing at random assumed in the imputa-
tion depends on the candidate risk factors. As long as the 
candidate risk factors considered in the study are comprehen-
sive, as in our study, this assumption is reasonable. Next, we 
applied the trained model and calculated the c-statistic on 
the cross-validation data for each step. The optimal number 
of steps (ie, the value of the boosting model hyperparameter) 
was the one that maximized the c-statistic averaged over all 
cross-validation iterations. The final model was then fitted 
using all data with the optimal hyperparameter value esti-
mated in the model-tuning exercise. Given the competing risk 
data, separate cause-specific hazard regression models were 
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fitted and tuned: 1 for SCD events and the other for non-SCD 
deaths. Because of a small number of patients with non-SCD 
deaths, we only applied 3-fold cross-validation to identify and 
quantify the risk factors associated with non-SCD deaths.
Model Performance 
On model fitting, both prognostic index and the 5-year cumu-
lative proportion of SCD events were quantified for each 
patient. The discriminatory power of the final model was 
quantified using the c-statistic for competing risk models.35 
Model calibration was assessed by stratifying patients into 3 
risk groups based on tertiles of the predicted 5-year probabil-
ity of a SCD event and by creating a calibration curve to show 
the relationship between the observed and predicted 5-year 
probability of events.
Model Validation 
The final model was externally validated using an indepen-
dent replication cohort consisting of 285 eligible patients 
from SHaRe after excluding 321 patients that overlapped 
with the discovery cohort. The Harrell c-statistic was calcu-
lated, and calibration curves were constructed using quantiles 
of predicted risk as described above.
RESULTS
The final derivation cohort consisted of 572 eligible 
patients with phenotype-positive HCM diagnosed be-
tween 1987 and 2018. This included 535 unrelated 
probands and 37 affected siblings of the probands. 
The distribution of cases by center and by age at di-
agnosis is shown in Figure I in the Data Supplement. 
Baseline clinical and echocardiographic characteristics 
at diagnosis for the primary and validation cohorts are 
displayed in Table 1. A total of 368 (64%) patients had 
asymmetrical septal hypertrophy. There were no cases 
of apical hypertrophy. The median age at diagnosis was 
9.8 years (interquartile range, 2.1–13.9). The median 
follow-up duration was 3.9 (1.5–6.7) years (duration to 
either death or the last known date alive). Of 565 pa-
tients, 336 (59%) received β-blockers during follow-up; 
medication data were not available in 7 patients. Of the 
311 (54%) subjects who had genetic testing reported, 
160 (28%) were identified as carrying at least 1 caus-
al pathogenic/likely pathogenic variant. The affected 
genes in the primary and validation cohorts are shown 
in Table I in the Data Supplement.
Time to SCD Events
Over the 2855 total patient-years of follow-up, 53 pa-
tients experienced a SCD event, including 14 sudden 
deaths, 25 resuscitated sudden cardiac arrests, and 14 
appropriate shocks in patients with primary preven-
tion ICDs. No patients in the cohort were phenotype 
negative at the time of a SCD event. Of the 102 pa-
tients who received an ICD for primary prevention, 14 
(13.7%)  experienced an appropriate shock; 88 did not 
experience an appropriate shock; of 23 patients with 
>5 years of follow-up after ICD, 3 (13%) experienced 
an appropriate shock. Overall, 7 experienced an inap-
propriate shock. Inappropriate shock information was 
unavailable in 19 patients (Figure II in the Data Supple-
ment). Figure III in the Data Supplement shows the in-
dications for primary prevention ICD implantation with 
63% patients receiving an ICD for a single indication. 
The median time to a SCD event from diagnosis was 
2.2 years (interquartile range, 0.9–5.2), and median age 
at an SCD event was 14.5 years (interquartile range, 
12.4–17.1). The cumulative proportion of SCD events 
at 1-year follow-up was 2.8% (95% CI, 1.4%–4.2%), 
and at 5 years was 9.1% (6.3%–11.9%) (Figure 1A).
Clinical Predictors of Time to SCD Events
The final clinical model included age at diagnosis, IVSD 
z score, LVPWD z score, LA diameter z score, peak LVOT 
gradient, nonsustained VT, and history of syncope. LA 
diameter z score was imputed in 21% patients in the 
overall cohort, and LVOT gradient was imputed in 29% 
patients in the overall cohort. Of the 53 patients who 
experienced a SCD event, LA diameter was imputed 
in 13%, and LVOT gradient was imputed in 17% pa-
tients. Our analysis suggested that a history of non-
sustained VT increased the likelihood of experiencing 
SCD events by 2.8-fold (hazard ratio [HR], 2.87 [95% 
CI, 1.00–6.57]), and a history of syncope increased the 
likelihood of experiencing SCD events by 7.4-fold (HR, 
7.40 [95% CI, 1.21–32.81]) (Table 2). A family history 
of SCD was not considered an important predictor ei-
ther in the overall cohort or in the subset with familial 
HCM. Figure 2 shows the regression-adjusted associa-
tion of the continuous risk factors with the composite 
outcome. Each panel summarizes the nonlinear asso-
ciation between a predictor and the SCD event. SCD 
risk increased with increased age at diagnosis, IVSD z 
score, LVPWD z score, and LA diameter z score. How-
ever, this positive correlation between IVSD and LVPWD 
z scores plateaued at a z score >20. In contrast, the risk 
associated with peak resting LVOT gradient remained 
flat when the gradient was ≤100 mm Hg and showed 
an inverse association with SCD risk as the gradient in-
creased further. For example, an increase in peak LVOT 
gradient from 100 to 120 mm Hg reduced the SCD risk 
by ≈10%. There was no difference in the cumulative 
proportion of SCD events in patients with and with-
out β-blocker use during follow-up (P=0.138) (data not 
shown). To further clarify the association with age, we 
compared outcomes in patients diagnosed before 5 
years of age versus later (Table II in the Data Supple-
ment). One-third of patients were diagnosed before 5 
years of age. They had a higher frequency of non-SCD 
deaths and transplant than those diagnosed later, and 
these non-SCD events occurred at a median age of <1 
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year. In contrast, early-onset HCM cases had an overall 
lower frequency of SCD events than those diagnosed 
later, but the median age at SCD events was not dif-
ferent, suggesting that the penetrance of SCD remains 
highest in adolescent and teenage years regardless of 
age at diagnosis. The overall lower frequency of SCD 
in early-onset cases may also be related, in part, to the 
higher non-SCD mortality and transplant in early life. 
There were no sex-related differences in the risk for 
SCD events.
Performance of the Clinical Prediction 
Model
The final clinical model was applied to the full co-
hort. The c-statistic was 0.75, indicating a good dis-
criminatory power. Subjects were stratified by tertile 
of predicted risk, and the cumulative proportion of 
SCD events over time was plotted for each tertile (Fig-
ure 2F). The difference in the cumulative proportion of 
SCD events across strata of predicted risk was signifi-
cant (P<0.001). Calibration (the agreement between 
Table 1. Clinical Characteristics of the PRIMaCY and SHaRe Cohorts
Clinical Characteristics Number Ascertained Variable* (PRIMaCY) Number Ascertained Variable* (SHaRe) P Value
Age at first evaluation, y 572 9.8 (2.1–13.9) 285 13.8 (8.3–16.2) <0.001
Male sex 572 394 (68.9) 285 199 (69.8) 0.81
Genetic testing done 572 311 (54.4) 285 166 (58.2) 0.315
Genetic testing results 311  166  0.024
  Positive  160 (51.4)  108 (65.0)  
  Inconclusive  66 (21.2)  27 (16.3)  
  Negative  85 (27.3)  31 (18.7)  
Family history of hypertrophic 
cardiomyopathy
550 264 (48.0) 285 102 (35.8) <0.001
Family history of SCD 572 105 (18.4) 206 29 (14.1) 0.196
Documented nonsustained ventricular 
tachycardia
572 18 (3.1) 88 7 (8) 0.037
History of unexplained syncope 572 17 (3.0) 285 6 (2.1) 0.51
Received β-blocker 565 336 (59.1) 284 127 (44.7) <0.001
Echocardiographic features at diagnosis, z score
  Interventricular septal diameter 572 9.5 (5.0–16.8) 283 9.4 (4.7–16.7) 0.66
  Left ventricular posterior wall diameter 566 2.4 (0.3–5.0) 269 2.4 (0.6–4.9) 0.43
  Left atrial diameter 453 1.1 (0.1–2.1) 190 1.4 (0.3–2.5) 0.035
  Peak resting left ventricular outflow tract 
gradient, mm Hg
401 13 (0.0–46.0) 90 10 (7–18) 0.81
  Left ventricular outflow tract obstructed 
(qualitative)
121 19 (16) 175 40 (23) 0.141
Survival outcomes
  SCD events 572 53 (9.3) 285 22 (7.7) <0.001
   SCD 572 14 (2.4) 285 8 (2.8)  
   Resuscitated sudden cardiac arrest 572 25 (4.4) 285 9 (3.2)  
   Appropriate shock with prophylactic 
implantable cardioverter-defibrillator
572 14* (2.4) 285 5 (1.8)  
Incidence rate†
  Years from diagnosis 572 3.9 (1.5–6.7) 285 3.9 (1.6–7.4)  
  Patient-years of follow-up 572 2855 285 1400  
  Outcomes
   Event free 572 17.9 285 18.3  
   SCD event 572 1.9 285 1.6  
   Non-SCD death 572 3.2 285 0.5  
Numbers in parentheses indicate percent, unless otherwise indicated. PRIMaCY indicates Precision Medicine for Cardiomyopathy; SCD, sudden cardiac death; and 
SHaRe, Sarcomeric Human Cardiomyopathy Registry. 
*Continuous variables were summarized using median and interquartile range; categorical variables were summarized using frequencies and proportions (%).
†Incidence rate refers to events per 100 patient-years of follow-up.
D
ow
nloaded from
 http://ahajournals.org by on October 7, 2020
Miron et al Predicting Sudden Death in Childhood HCM
July 21, 2020 Circulation. 2020;142:217–229. DOI: 10.1161/CIRCULATIONAHA.120.047235222
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
the magnitude of predicted risk versus observed risk) 
was assessed by stratifying predicted risk into tertiles 
and plotting the observed cumulative proportion of 
SCD events over time against the mean predicted risk 
for that tertile. This showed that subjects with predict-
ed risk in the highest tertile had the highest observed 
cumulative proportion of SCD events and subjects in 
the lowest tertile of model-predicted risk had the low-
est observed cumulative proportion of SCD events. 
The calibration curve in Figure 2G shows good agree-
ment between predicted and observed 5-year cumula-
tive proportion of SCD events for each tertile of pre-
dicted risk (Table 3).
Clinical and Genetic Predictors of Time to 
SCD Events
The first clinical/genetic model was generated using 
all clinical predictors discussed earlier along with a 
genotype-positive status. Similar to the clinical model, 
SCD risk was higher with a history of nonsustained VT 
(HR, 2.58 [95% CI, 1.00–6.17]), and a history of syn-
cope (HR, 7.23 [95% CI, 1.09–33.57]). In addition, the 
presence of a pathogenic/likely pathogenic variant (ie, 
being genotype positive) elevated the likelihood of ex-
periencing SCD events (HR, 1.32 [95% CI, 1.00–2.12]) 
in comparison with the confirmed absence of a patho-
genic variant on genetic testing (Table 2). For continu-
ous risk factors, Figure 3 shows the regression-adjusted 
effects of the predictors on the primary outcome with a 
relationship similar to the clinical model.
Performance of the Combined Clinical/
Genetic Model
The final clinical/genetic model was applied to the 
full cohort to generate a cumulative proportion curve 
for 5-year incidence of SCD events. This showed the 
ability of the risk prediction model to discriminate be-
tween 3 tertiles of SCD risk similar to the clinical model 
(P<0.001) (Figure 3F). Figure 3G shows the calibration 
curve for the 3 risk tertiles with good agreement be-
tween predicted and observed SCD event–free survival 
with an overall c-statistic of 0.762, which was similar to 
the clinical model (Table 3).
Other Models Considered
Because the genes involved can influence the risk of 
SCD, we also explored the association of a patho-
genic/likely pathogenic variant in MYH7, MYBPC3, 
or other HCM-associated genes, that is, gene-specific 
associations versus confirmed absence of a variant. 
The presence of a pathogenic/likely pathogenic vari-
ant in MYBPC3 was associated with a higher risk of 
SCD events but the increase in risk was modest, with 
a HR, 1.022 (95%, 1.00–1.78). The c-statistic of this 
model was 0.726, which was lower than that of the 
Figure 1. Cumulative proportion of SCD events estimated using competing risk models in PRIMaCY and SHaRe cohorts.
A, PRIMaCY cohort (n=572): The cumulative proportion of SCD events in patients with pediatric HCM at 1-year follow-up was 2.8% (95% CI, 1.4%–4.2%), at 5 
years was 9.1% (95% CI, 6.3%–11.9%), and at 10 years was 15.0% (95% CI, 10.0%–19.7%). The cumulative proportion of death from other causes at 1-year 
follow-up was 0.9% (95% CI, 0.1%–1.8%), at 5 years was 1.8% (95% CI, 0.6%–3.0%), and at 10 years was 1.8% (95% CI, 0.6%–3.0%). B, SHaRe cohort 
(n=285): The cumulative proportion of SCD events at 1-year follow-up was 2.3% (95% CI, 0.5%–4.1%), at 5 years was 6.8% (95% CI, 3.2%–10.3%), and at 
10 years was 13.7% (95% CI, 6.5%–20.4%). The cumulative proportion of death from other causes at 1-year follow-up was 0.7% (95% CI, 0.0%–1.7%), at 5 
years was 2.1% (95% CI, 0.2%–3.9%), and at 10 years was 4.5% (95% CI, 0.6%–8.2%). Echo indicates echocardiogram; HCM, hypertrophic cardiomyopathy; 
PRIMaCY, Precision Medicine for Cardiomyopathy Study; SCD, sudden cardiac death; and SHaRe, Sarcomeric Human Cardiomyopathy Registry. 
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first genetic model. Therefore, this model was not 
considered for further validation. The study was not 
powered to examine the effect of variant burden on 
SCD risk because only 2.8% patients harbored mul-
tiple pathogenic variants.
External Validation
For independent validation of the risk prediction mod-
els, we analyzed 285 phenotype-positive patients with 
childhood-onset HCM from SHaRe. There were minor 
differences in clinical characteristics between the SHaRe 
and the primary cohorts. The SHaRe patients were old-
er at diagnosis, and the racial distribution was 89.6% 
White, 4.5% Asian, and 5.2% Black (Table 1). A higher 
proportion was genotype positive, a lower proportion 
was familial, and a higher proportion had nonsustained 
VT and higher LA diameter z scores at baseline. The 
type of SCD events are shown in Figure IV in the Data 
Supplement. The cumulative proportion of SCD events 
at 1-year follow-up was 2.3% (0.5%–4.1%), and at 5 
years was 6.8% (3.2%–10.3%) with a total of 22 SCD 
events over a median follow-up of 3.3 (1.3–7.0) years 
(Figure 1B). The incidence of SCD events was not signif-
icantly different from the discovery cohort (P=0.57). Pa-
tients in the replication cohort were scored using both 
risk prediction models, and the performance of each 
model in the validation cohort was assessed. The c-
statistic was 0.707 for the clinical model and 0.724 for 
the clinical/genetic model with acceptable agreement 
between the predicted and observed 5-year cumulative 
proportion of SCD events for both models.
DISCUSSION
The incidence of sudden cardiac death in pediatric 
HCM is significantly higher than in adults.28 The 5-year 
risk of a SCD event in our study was 9.1%. Howev-
er, only 25% received an ICD that was able to abort 
the event. The remaining patients either died without 
an ICD or received an ICD only after experiencing the 
event. In addition, of the 102 patients in the cohort 
who received a primary prevention ICD, 86% did not 
receive an appropriate shock including many who had 
a 5-year follow-up. This is comparable to adult studies 
and highlights a major gap in knowledge on how to 
risk stratify for sudden death in the pediatric popula-
tion.14,36,37 The practice guidelines to date have relied 
on adult markers for risk stratifying children and ado-
lescents.4 Using data from a multicenter consortium of 
pediatric HCM centers, we found important differences 
in risk factors between children and adults. Using age-
specific risk factors, we developed and validated a pe-
diatric SCD risk prediction model that can bridge this 
gap in knowledge and provide the evidence needed by 
clinicians to assist in decision making for SCD preven-
tion. At present, only 1 in 9 prophylactic ICDs are ap-
propriate implantations.38 The use of a prediction tool 
has the potential to increase appropriate ICD implan-
tation while reducing unwanted ICD implantation in a 
vulnerable population that is at higher risk of ICD com-
plications because of their small size and physiological 
differences from adults.
To develop this model, we used an evidence-based 
approach to determine whether the conventional risk 
factors for SCD identified mostly through adult studies 
apply to children. Our analysis confirmed the positive 
association of age, history of syncope, nonsustained 
VT, LV wall thickness, and LA diameter with SCD risk, 
but also revealed some important differences between 
pediatric and adult risk factors. For example, although 
there was a linear relationship between septal thickness 
and SCD risk, the risk plateaued with massive septal 
hypertrophy suggesting that, unlike in adults, there was 
no clear septal z score threshold that conferred an in-
dependent risk of SCD. Also, there was no significant 
association between peak resting LVOT gradient with 
SCD, and there was an inverse association with SCD 
at very high gradients. This was likely not related to 
medication use because SCD event frequency was not 
different by β-blocker use. It is not clear if this could be 
related to a possible protective effect of septal myec-
tomy in patients with high gradients.9,39 The finding of 
a positive association of age with SCD risk is consistent 
with the known higher penetrance of SCD in adoles-
cents and teenagers.7 The overall lower frequency of 
SCD in early-onset cases may also be related in part to 
a lower survival into teenage years because of a high-
er non-SCD mortality and transplant in early life. The 
difference in outcomes is unlikely to be related to the 
presence of nonsarcomeric gene variants in younger 
patients (all of whom had isolated HCM at the time of 
diagnosis and follow-up) because nonsarcomeric gene 
variants accounted for <3% of early-onset cases. Our 
previous work has shown that the sarcomeric genotype 
itself can influence disease onset and severity with the 
affected sarcomeric gene, variant burden, and de novo 
status associated with earlier-onset HCM and lower 
Table 2. Categorical Predictors of 5-Year Sudden Cardiac Death Risk
Model Hazard Ratios (95% CI)
Clinical
  Prior history of nonsustained ventricular 
tachycardia
2.87 (1.00–6.57)
  Prior history of syncope 7.40 (1.21–32.81)
Clinical/genetic 
  Prior history of nonsustained ventricular 
tachycardia
2.58 (1.00–6.17)
  Prior history of syncope 7.23 (1.09–33.57)
  Pathogenic variant in any gene (reference: 
confirmed absence of variant)
1.32 (1.00–2.12)
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Figure 2. Regression-adjusted effects of continuous covariates and clinical SCD risk prediction model performance (n=572).
A through E, The top of each figure shows the observed values of the continuous risk predictor among patients with pediatric HCM in the training cohort who 
experienced the composite SCD outcome; the bottom shows the observed values of the predictor among those who did not experience (Continued )
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freedom from not just SCD, but also the need for myec-
tomy, transplant, or death.40
We noted that a family history of SCD did not 
emerge as a significant risk factor, which may be so 
for several reasons, including the often sporadic oc-
currence of childhood HCM, a higher likelihood that 
SCD events may not have manifested yet in young 
adult relatives of child probands, and the limitation in 
tracking all family SCD events in a retrospective study 
design. Furthermore, family history may be protective 
because it prompts screening, early diagnosis, and 
timely follow-up and interventions in family members. 
The lack of statistically significant associations between 
family history of SCD and LVOT gradient with SCD risk 
in childhood HCM is consistent with other recently 
published reports.7,41–43
Prior studies have reported that patients carrying at 
least 1 pathogenic/likely pathogenic variant were more 
likely to experience earlier disease onset and worse pa-
tient outcomes.10,23,24,40,44,45 This aligns with our finding 
that genotype-positive individuals had a 1.3-fold higher 
risk of experiencing a SCD event than individuals who 
were genotype negative on genetic testing after ac-
counting for all clinical risk factors. In a first attempt 
to incorporate genetic risk into the prediction model, 
we observed only a modest difference in prediction ac-
curacy between the clinical and combined models. The 
failure to see a larger difference may be related to the 
limited uptake of genetic testing whereby only 54% pa-
tients had undergone genetic testing with less than one-
third being genotype positive. We also explored the ef-
fect of incorporating affected gene and variant burden 
into the model but were likely underpowered to identify 
meaningful genotype-specific differences in SCD risk. 
Larger studies are needed to analyze and incorporate 
genotype-specific differences in risk predictions.
Last, our model provided a good prediction accura-
cy with a c-statistic of 0.75 in comparison with a recent 
study in a UK cohort where the c-statistic was 0.69 in 
the training set with no external validation.28 The UK 
study included 5 preselected risk factors that were not 
reevaluated before inclusion in the model. Their model 
did not include age at diagnosis, and did not differen-
tiate between IVSD and LVPWD z scores as indepen-
dent predictors of SCD risk, but instead used maximal 
LV wall thickness in any segment. We reevaluated all 
potential risk factors to ensure that all evidence-based 
risk factors were included and the nonlinear relation-
ship of the risk factors with SCD risk was incorporated 
into the model to improve its accuracy. We were able 
to externally validate the clinical and clinical/genetic 
models, as well, using an independent cohort. The pre-
dictive accuracy of both models remained >0.7, which 
is comparable in performance to the adult SCD risk 
calculator in clinical use.18 The decrease in c-statistic 
in the validation cohort may have been related to a 
nonsignificantly lower SCD event rate attributable to 
a potential survivor bias, because the SHaRe validation 
cohort was composed predominantly of adult-age sur-
vivors of childhood-onset HCM.
Clinical Significance
There is an important potential for our findings to as-
sist in clinical decision making to prevent one of the 
most tragic outcomes of pediatric HCM. Our study re-
ports the only independently validated model for SCD 
risk prediction in pediatric HCM, and the only study 
that provides evidence from a large ethnically and geo-
graphically relevant North American pediatric cohort. 
Our findings reinforce that most SCD risk factors are 
not binary and that, in children, the decision for ICD 
Table 3. Observed Versus Model-Predicted 5-Year Freedom From Sudden Cardiac Death (n=572)
Risk Group Categories Risk Tertile, %
Average Predicted 
Risk, %
Observed Risk, 
%(95% CI) C-Statistic
Clinical model 
  Low risk <4.7 3.4 2.8 (1.1–7.6) 0.750
  Medium risk 4.7–8.3 6.3 7.2 (3.9–13.4)  
  High risk >8.3 20.0 18.5 (12.7–26.9)  
Clinical/genetic model
  Low risk <4.7 3.3 1.9 (0.6–5.9) 0.762
  Medium risk 4.7–8.3 6.2 7.6 (4.1–14.1)  
  High risk >8.3 20.0 18.8 (13.1–27.1)  
Figure 2 Continued. the composite SCD outcome. SCD risk increased with age at diagnosis (A); increase in IVSD z score (B); LVPWD z score (C); and LA diameter 
z score (D). E, The risk associated with peak resting LVOT gradient remained flat when the gradient was ≤100 mm Hg and decreased as the gradient increased to 
>100 mm Hg. F, The cumulative proportion of SCD events stratified by tertiles of risk predicted by the clinical-only model, that is, predicted risk <4.7%, 4.7% to 
8.3%, and >8.3%. G, The calibration curve for the clinical model applied to the training cohort shows the predicted versus the observed 5-year risk of the com-
posite SCD outcome. The prediction accuracy, that is, c-statistic of the model, was 0.75. The dashed line, the 45° line through 0, represents a perfectly calibrated 
model between the observed and the predicted 5-year survival probabilities. Echo indicates echocardiogram; HCM, hypertrophic cardiomyopathy; IVSD, interven-
tricular septal diameter; LA, left atrium; LVOT, left ventricular outflow tract; LVPWD, left ventricular posterior wall diameter; and SCD, sudden cardiac death.
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Figure 3. Regression-adjusted effects of continuous covariates and clinical/genetic SCD risk prediction model performance (n=572).
A through E, The top of each figure shows the observed values of the continuous risk predictor among patients with pediatric HCM in the training cohort who 
experienced the composite SCD outcome; the bottom shows the observed values of the predictor among those who did not experience the composite SCD out-
come. SCD risk increased with age at first evaluation (A); increase in IVSD z score (B); LVPWD z score (C); and LA diameter z score (D). (Continued )
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should not be made on the basis of a single risk fac-
tor, especially given the higher ICD complication rates 
in this age group. The model ensures that all validated 
risk factors are considered in the decision-making pro-
cess by using an unbiased approach.46 The algorithm 
we have developed not only encapsulates practice rec-
ommendations but also provides an individualized esti-
mate of 5-year sudden death risk that can be used in 
ICD shared decision making between patient and pro-
vider as opposed to a binary classification of high versus 
low risk. The American College of Cardiology/Ameri-
can Heart Association guidelines include the following 
class I recommendation, highlighting the emphasis on 
shared decision making for ICD between patients and 
providers: “The decision to place an ICD in patients 
with HCM should include application of individual clini-
cal judgment, as well as a thorough discussion of the 
strength of evidence, benefits and risks to allow the 
informed patient’s active participation in decision mak-
ing.”4 Ultimately, this model has the potential for use 
as a decision support tool to facilitate ICD shared deci-
sion making through individualized risk prediction, and 
improve clinical outcomes through appropriate ICD use 
in high-risk patients.
Limitations
The study has limitations inherent to any retrospective 
analysis, that includes missing data, survivor bias, and 
lower uptake of genetic testing in the earlier era. Miss-
ing echocardiographic data were addressed through 
a re-review of echocardiograms where available and 
through imputation where this was not possible. We 
deliberately did not perform an echocardiographic core 
laboratory analysis because a real-world, point-of-care 
tool has to rely on locally acquired data. We did how-
ever standardize the calculations for z score measure-
ments. Our study did not include emerging risk factors 
like late gadolinium enhancement on cardiac magnetic 
resonance imaging because of challenges related to the 
low yield of late gadolinium enhancement in children, 
lack of a clear definition for an abnormal cutoff espe-
cially in children, variability in cardiac magnetic reso-
nance imaging use across centers, and the inability to 
perform this test in younger children without sedation 
that limits universal clinical use at this time. Atypical ven-
tricular phenotypes such as apical aneurysm formation, 
which are rare in pediatric HCM, were also not included 
as risk factors. Although some patients harbored vari-
ants in nonsarcomeric genes like RASopathy-associated 
genes, we confirmed that patients were nonsyndromic 
at the time of clinical ascertainment and did not have 
a phenotype consistent with a syndromic, metabolic, 
or neuromuscular phenotype. We recognize that some 
appropriate ICD discharges may have been for self-ter-
minating VT/ventricular fibrillation which can overesti-
mate SCD. Antitachycardia pacing events were also not 
captured. Despite an acceptable predictive accuracy of 
our model at present, we recognize that childhood and 
adolescence are times of significant dynamic change 
in cardiac growth and phenotypic expression. Future 
iterations of the model will need to be dynamic and in-
corporate the trajectory of phenotypic change in HCM 
with time to further improve prediction accuracy.
CONCLUSIONS
The independently validated PRIMaCY model has 
>70% accuracy for SCD risk prediction in pediatric 
HCM. We anticipate that clinical uptake of this model 
of risk prediction will improve the application of clini-
cal practice guidelines, facilitate shared decision mak-
ing around ICD implantation through individualized 
risk prediction, and improve clinical outcomes through 
appropriate ICD use in high-risk pediatric patients 
while avoiding ICDs in low-risk patients. An important 
future goal will be to incorporate this model into hos-
pital electronic health systems as a point-of-care tool 
for physicians and to assess the implementation effec-
tiveness of this approach in the application of clinical 
practice guidelines.
ARTICLE INFORMATION
Received April 1, 2020; accepted April 29, 2020.
Continuing medical education (CME) credit is available for this article. Go 
to http://cme.ahajournals.org to take the quiz.
The Data Supplement is available with this article at https://www.ahajournals.
org/doi/suppl/10.1161/CIRCULATIONAHA.120.047235.
Authors
Anastasia Miron, HBA; Myriam Lafreniere-Roula, PhD; Chun-Po Steve Fan, 
PhD, PStat; Katey R. Armstrong, MBChB, MD; Andreea Dragulescu, MD, PhD; 
Tanya Papaz, HBA; Cedric Manlhiot, PhD; Beth Kaufman, MD; Ryan J. Butts, 
MD; Letizia Gardin, MD; Elizabeth A. Stephenson, MD; Taylor S. Howard, MD; 
Pete F. Aziz, MD; Seshadri Balaji, MBBS, MRCP(UK), PhD; Virginie Beauséjour 
Ladouceur, MD; Lee N. Benson, MD; Steven D. Colan, MD; Justin Godown, MD; 
Heather T. Henderson, MD; Jodie Ingles, PhD, MPH; Aamir Jeewa, MD; John L. 
Jefferies, MD, MPH; Ashwin K. Lal, MD; Jacob Mathew, MBBS; Emilie Jean-St-
Michel, MD CM, MSc; Michelle Michels, MD, PhD; Stephanie J. Nakano, MD; 
Iacopo Olivotto, MD; John J. Parent, MD, MS; Alexandre C. Pereira, MD, PhD; 
Christopher Semsarian, MBBS, PhD, MPH; Robert D. Whitehill, MD; Samuel 
G. Wittekind, MD, MSc; Mark W. Russell, MD; Jennifer Conway, MD; Marc E. 
Figure 3 Continued. E, The risk associated with peak resting LVOT gradient remained flat when the gradient was ≤100 mm Hg and decreased as the gradient 
increased above 100 mm Hg. F, Cumulative proportion of SCD events stratified by tertiles of risk predicted by the clinical/genetic model, that is, predicted risk 
<4.7%, 4.7% to 8.3%, and >8.3%. G, The calibration curve for the clinical/genetic model applied to the training cohort shows the predicted versus the ob-
served 5-year risk of the composite SCD outcome. The prediction accuracy, that is, c-statistic of the model, was 0.762. The dashed line, the 45° line through 0, 
represents a perfectly calibrated model between the observed and the predicted 5-year survival probabilities. Echo indicates echocardiogram; HCM, hypertro-
phic cardiomyopathy; IVSD, interventricular septal diameter; LA, left atrium; LVOT, left ventricular outflow tract; LVPWD, left ventricular posterior wall diameter; 
and SCD, sudden cardiac death.
D
ow
nloaded from
 http://ahajournals.org by on October 7, 2020
Miron et al Predicting Sudden Death in Childhood HCM
July 21, 2020 Circulation. 2020;142:217–229. DOI: 10.1161/CIRCULATIONAHA.120.047235228
OR
IG
IN
AL
 R
ES
EA
RC
H 
AR
TI
CL
E
Richmond, MD, MS; Chet Villa, MD; Robert G. Weintraub, MBBS; Joseph W. 
Rossano, MD; Paul F. Kantor, MBBCh; Carolyn Y. Ho, MD; Seema Mital, MD
Correspondence
Seema Mital, MD, Hospital for Sick Children, 555 University Avenue, Toronto, 
Ontario M5G 1X8, Canada. Email seema.mital@sickkids.ca
Affiliations
Division of Cardiology (A.M., T.P., S.M.), Department of Cardiology (A.D., V.B.L., 
L.N.B., A.J., E.J.-St-M.), Hospital for Sick Children, Toronto, Ontario, Canada. 
Ted Rogers Computational Program, Ted Rogers Center for Heart Research, The 
Hospital for Sick Children, University Health Network, Toronto, Ontario, Canada 
(M.L.-R., C.-P,S.F.). Division of Pediatric Cardiology, Department of Pediatrics, 
British Columbia Children’s Hospital, Vancouver, Canada (K.R.A.). Department 
of Pediatrics, Johns Hopkins Medical Center, Baltimore, MD (C.M.). Department 
of Pediatrics, Lucile Packard Children’s Hospital Stanford, Palo Alto, CA (B.K.). 
Division of Pediatric Cardiology, Department of Pediatrics, Children’s Medical 
Center of Dallas, TX (R.J.B.). Department of Cardiology, Children’s Hospital of 
Eastern Ontario, Ottawa, Ontario, Canada (L.G.). Department of Cardiology, 
Labatt Family Heart Center, Hospital for Sick Children, University of Toronto, 
Ontario, Canada (E.A.S., S.M.). Department of Pediatrics, Section of Pediatric 
Cardiology, Baylor College of Medicine, Texas Children’s Hospital (T.S.H.). Cen-
ter for Pediatric and Congenital Heart Disease, Pediatric Electrophysiology and 
Pacing, Cleveland Clinic Children’s Hospital, OH (P.F.A.). Department of Pediat-
rics, Division of Cardiology, Oregon Health & Science University, OHSU Doern-
becher Children’s Hospital, Portland (S.B.). Department of Cardiology, Boston 
Children’s Hospital, MA (S.D.C.). Department of Pediatrics, Division of Pediatric 
Cardiology, Monroe Carrell Jr Children’s Hospital at Vanderbilt, Nashville, TN 
(J.G.). Pediatrics, Medical University of South Carolina, Charleston (H.T.H.). Ag-
nes Ginges Center for Molecular Cardiology at Centenary Institute, The Uni-
versity of Sydney, New South Wales, Australia (J.I., C.S.). Division of Adult Car-
diovascular Diseases, University of Tennessee Health Science Center, Memphis 
(J.L.J.). Division of Pediatric Cardiology, University of Utah Primary Children’s 
Hospital, Salt Lake City (A.K.L.). Department of Cardiology, The Royal Children’s 
Hospital, Melbourne, Victoria, Australia (J.M., R.G.W.). Department of Cardiol-
ogy, Thoraxcenter, Erasmus MC Rotterdam, South Holland, Netherlands (M.M.). 
Department of Pediatrics, Division of Cardiology, Children’s Hospital Colorado, 
Aurora (S.J.N.). Referral Center for Cardiomyopathies, Careggi University Hos-
pital, Florence, Italy (I.O.). Department of Pediatrics, Riley Children’s Hospital, 
Indianapolis, IN (J.J.P.). Laboratory of Genetics and Molecular Cardiology, Heart 
Institute (InCor), University of Sao Paulo Medical School, Brazil (A.C.P.). Divi-
sion of Cardiology, Children’s Healthcare of Atlanta, GA (R.D.W.). The Heart 
Institute, Cincinnati Children’s Hospital, OH (S.G.W., C.V.). Pediatrics, C.S. Mott 
Children’s Hospital, Ann Arbor, MI (M.W.R.). Division of Pediatric Cardiology, 
Department of Pediatrics, Stollery Children’s Hospital, Edmonton, AB, Canada 
(J.C.). Division of Pediatric Cardiology, Department of Pediatrics, Columbia Uni-
versity College of Physicians and Surgeons/Morgan Stanley Children’s Hospital, 
New York, NY (M.E.R.). Murdoch Children’s Research Institute, University of 
Melbourne, Victoria, Australia (R.G.W.). Division of Cardiology, Children’s Hos-
pital of Philadelphia, PA (J.W.R.). Division of Cardiology, Children’s Hospital of 
Los Angeles, CA (P.F.K.). Cardiovascular Division, Brigham and Women’s Hospi-
tal, Boston, MA (C.Y.H.).
Sources of Funding
The project was supported through funding from the Ted Rogers Center for 
Heart Research, and the Heart and Stroke Foundation/Robert M Freedom Chair 
(to Dr Mital). Dr Ingles was supported by a National Health and Medical Re-
search Council Career Development Fellowship (no. 1162929). Dr Semsarian 
was supported by an National Health and Medical Research Council Practitioner 
Fellowship (no. 1154992).
Disclosures
Dr Balaji is a consultant for Milestone Pharmaceuticals and is on the medical 
advisory board for Yor Labs. Dr Conway is a Medical Monitor for the Pumpkin 
Trial and has received unrestricted education funding from Abbott. Dr Ros-
sano is a consultant for Amgen, Bayer, Novartis, and CLS Behring. Dr Kantor 
is a consultant for Novartis and Astra-Zeneca. Drs Colan, Ingles, Olivotto, 
Russell, and Ho received research grant support and consultation fees from 
Myokardia Inc.
Supplemental Materials
Data Supplement Figures I–IV
Data Supplement Tables I–II
REFERENCES
 1. Liew AC, Vassiliou VS, Cooper R, Raphael CE. Hypertrophic cardiomy-
opathy-past, present and future. J Clin Med. 2017;6:118. doi: 10.3390/ 
jcm6120118
 2. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. 
Prevalence of hypertrophic cardiomyopathy in a general population 
of young adults. Circulation. 1995;92:785–789. doi: 10.1161/01.cir. 
92.4.785
 3. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prev-
alence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015;65:1249–
1254. doi: 10.1016/j.jacc.2015.01.019
 4. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, 
Nishimura RA, Ommen SR, Rakowski H, et al; American College of Car-
diology Foundation/American Heart Association Task Force on Practice 
Guidelines. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment 
of Hypertrophic Cardiomyopathy: a report of the American College of 
Cardiology Foundation/American Heart Association Task Force on Practice 
Guidelines. Developed in collaboration with the American Association for 
Thoracic Surgery, American Society of Echocardiography, American Soci-
ety of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm 
Society, Society for Cardiovascular Angiography and Interventions, and 
Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e212–e260. doi: 
10.1016/j.jacc.2011.06.011
 5. Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mecha-
nistic insights into the  genetics of cardiomyopathy. J Am Coll Cardiol. 
2016;68:2871–2886. doi: 10.1016/j.jacc.2016.08.079
 6. O’Mahony C, Tome Esteban MT, Lambiase P, Pantazis A, Dickie S, 
McKenna W, Elliott P. A validation study of the 2003 American College of 
Cardiology/European Society of Cardiology and 2011 American College 
of Cardiology Foundation/American Heart Association risk stratification 
and treatment algorithms for sudden cardiac death in patients with hy-
pertrophic cardiomyopathy. Heart. 2013;99:534–541.
 7. Norrish G, Ding T, Field E, McLeod K, Ilina M, Stuart G, Bhole V, Uzun O, 
Brown E, Daubeney PEF, et al. A validation study of the European Society 
of Cardiology guidelines for risk stratification of sudden cardiac death in 
childhood hypertrophic cardiomyopathy. Europace. 2019;21:1559–1565. 
doi: 10.1093/europace/euz118
 8. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, 
Estes NA 3rd, Shannon KM, Ashley EA, Day SM, Pacileo G, et al. 
Prevention of sudden cardiac death with implantable cardioverter-
defibrillators in children and adolescents with hypertrophic cardiomy-
opathy. J Am Coll Cardiol. 2013;61:1527–1535. doi: 10.1016/j.jacc. 
2013.01.037
 9. Nakano SJ, Menon SC. Risk stratification in pediatric hypertrophic cardio-
myopathy: Insights for bridging the evidence gap? Prog Pediatr Cardiol. 
2018;49:31–37. doi: 10.1016/j.ppedcard.2018.03.001
 10. Maurizi N, Passantino S, Spaziani G, Girolami F, Arretini A, Targetti M, 
Pollini I, Tomberli A, Pradella S, Calabri GB, et al. Long-term outcomes 
of pediatric-onset hypertrophic cardiomyopathy and age-specific risk fac-
tors for lethal arrhythmic events. JAMA Cardiol. 2018;3:520–525. doi: 
10.1001/jamacardio.2018.0789
 11. Krause U, Müller MJ, Wilberg Y, Pietzka M, Backhoff D, Ruschewski W, 
Paul T. Transvenous and non-transvenous implantable cardioverter-defi-
brillators in children, adolescents, and adults with congenital heart dis-
ease: who is at risk for appropriate and inappropriate shocks? Europace. 
2019;21:106–113. doi: 10.1093/europace/euy219
 12. Kaski JP, Tomé Esteban MT, Lowe M, Sporton S, Rees P, Deanfield JE, 
McKenna WJ, Elliott PM. Outcomes after implantable cardioverter-defi-
brillator treatment in children with hypertrophic cardiomyopathy. Heart. 
2007;93:372–374. doi: 10.1136/hrt.2006.094730
 13. DeWitt ES, Triedman JK, Cecchin F, Mah DY, Abrams DJ, Walsh EP, 
Gauvreau K, Alexander ME. Time dependence of risks and benefits in 
pediatric primary prevention implantable cardioverter-defibrillator ther-
apy. Circ Arrhythm Electrophysiol. 2014;7:1057–1063. doi: 10.1161/ 
CIRCEP.114.001569
 14. Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, 
Ahmed A, Boriani G, Francia P, Winters SL, et al. Clinical course and 
quality of life in high-risk patients with hypertrophic cardiomyopathy 
D
ow
nloaded from
 http://ahajournals.org by on October 7, 2020
Miron et al Predicting Sudden Death in Childhood HCM
Circulation. 2020;142:217–229. DOI: 10.1161/CIRCULATIONAHA.120.047235 July 21, 2020 229
ORIGINAL RESEARCH 
ARTICLE
and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol. 
2018;11:e005820. doi: 10.1161/CIRCEP.117.005820
 15. Prinz C, Vogt J, Bitter T, Muntean BG, Hering D, Horstkotte D, Faber L. 
Incidence of adequate ICD interventions in patients with hypertrophic car-
diomyopathy supposed to be at high risk for sudden cardiac death. Acta 
Cardiol. 2010;65:521–525. doi: 10.1080/ac.65.5.2056238
 16. Iwai S. Sudden cardiac death risk stratification and the role of the im-
plantable cardiac defibrillator. Cardiol Clin. 2019;37:63–72. doi: 
10.1016/j.ccl.2018.08.011
 17. Berul CI, Van Hare GF, Kertesz NJ, Dubin AM, Cecchin F, Collins KK, 
Cannon BC, Alexander ME, Triedman JK, Walsh EP, et al. Results of a 
multicenter retrospective implantable cardioverter-defibrillator registry 
of pediatric and congenital heart disease patients. J Am Coll Cardiol. 
2008;51:1685–1691. doi: 10.1016/j.jacc.2008.01.033
 18. O’Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, 
Cecchi F, Olivotto I, Kitaoka H, Gotsman I, et al. International external 
validation study of the 2014 European Society of Cardiology Guide-
lines on Sudden Cardiac Death Prevention in Hypertrophic Cardio-
myopathy (EVIDENCE-HCM). Circulation. 2018;137:1015–1023. doi: 
10.1161/CIRCULATIONAHA.117.030437
 19. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, 
Biagini E, Gimeno JR, Limongelli G, McKenna WJ, et al. A novel clinical 
risk prediction model for sudden cardiac death in hypertrophic cardiomy-
opathy (HCM Risk-SCD). Eur Heart J. 2013;35:2010–2020.
 20. Maron M, Rowin E, Maron BJ. Increasing evidence that risk scores un-
derperform in predicting sudden death in hypertrophic cardiomyopathy. 
Heart. 2019;105:1850–1851. doi: 10.1136/heartjnl-2019-315694
 21. O’Mahony C, Akhtar MM, Anastasiou Z, Guttmann OP, Vriesendorp PA, 
Michels M, Magrì D, Autore C, Fernández A, Ochoa JP, et al. Effectiveness 
of the 2014 European Society of Cardiology guideline on sudden cardiac 
death in hypertrophic cardiomyopathy: a systematic review and meta-
analysis. Heart. 2019;105:623–631. doi: 10.1136/heartjnl-2018-313700
 22. Armstrong K, Jeon J, Fan Chun-Po S, Manlhiot C, Wilson J, George K, 
Stephenson E, Mital S. Abstract 17056: validation of the adult hypertro-
phic cardiomyopathy sudden death risk calculator in a pediatric popula-
tion. Circulation. 2016;134:A17056–A17056.
 23. Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, 
Fox JC, Lakdawala NK, Ware JS, et al. Genotype and lifetime burden of 
disease in hypertrophic cardiomyopathy: insights from the Sarcomeric 
Human Cardiomyopathy Registry (SHaRe). Circulation. 2018;138:1387–
1398. doi: 10.1161/CIRCULATIONAHA.117.033200
 24. Kelly M, Semsarian C. Multiple mutations in genetic cardiovascular dis-
ease: a marker of disease severity? Circ Cardiovasc Genet. 2009;2:182–
190. doi: 10.1161/CIRCGENETICS.108.836478
 25. Leong KMW, Chow JJ, Ng FS, Falaschetti E, Qureshi N, Koa-Wing M, 
Linton NWF, Whinnett ZI, Lefroy DC, Davies DW, et al. Comparison 
of the prognostic usefulness of the European Society of Cardiol-
ogy and American Heart Association/American College of Cardiology 
Foundation Risk Stratification Systems for Patients With Hypertrophic 
Cardiomyopathy. Am J Cardiol. 2018;121:349–355. doi: 10.1016/j. 
amjcard.2017.10.027
 26. Maron MS, Rowin EJ, Maron BJ. The ESC risk score is less reliable than 
ACC/AHA risk factors in hypertrophic cardiomyopathy: when sen-
sitivity trumps specificity. Can J Cardiol. 2019;35:1626–1628. doi: 
10.1016/j.cjca.2019.06.018
 27. Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, 
Romashko M, Link MS, Maron BJ. Enhanced American College of Cardiol-
ogy/American Heart Association strategy for prevention of sudden cardiac 
death in high-risk patients with hypertrophic cardiomyopathy. JAMA Car-
diol. 2019;4:644–657. doi: 10.1001/jamacardio.2019.1391
 28. Norrish G, Ding T, Field E, Ziólkowska L, Olivotto I, Limongelli G, 
Anastasakis A, Weintraub R, Biagini E, Ragni L, et al. Development of 
a novel risk prediction model for sudden cardiac death in childhood hy-
pertrophic cardiomyopathy (HCM Risk-Kids). JAMA Cardiol. 2019;4:918–
927. doi: 10.1001/jamacardio.2019.2861
 29. Colan SD. Normal echocardiographic values for cardiovascular structures. 
In: Lai WW, Mertens LL, Cohen MS. eds. Echocardiography in Pediatric 
and Congenital Heart Disease: From Fetus to Adult. 2nd ed. Hoboken, NJ: 
John Wiley & Sons Ltd; 2016:883–901.
 30. Sluysmans T, Colan SD. Structural measurements and adjustments for 
growth. In: Lai WW, Mertens LL, Cohen MS. eds. Echocardiography in 
Pediatric and Congenital Heart Disease: From Fetus to Adult. 2nd ed. 
Hoboken, NJ: John Wiley & Sons Ltd; 2016:61–72.
 31. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, 
Hegde M, Lyon E, Spector E, et al; ACMG Laboratory Quality Assurance 
Committee. Standards and guidelines for the interpretation of sequence 
variants: a joint consensus recommendation of the American College of 
Medical Genetics and Genomics and the Association for Molecular Pathol-
ogy. Genet Med. 2015;17:405–424. doi: 10.1038/gim.2015.30
 32. Wreede L, Fiocco M, Putter H. Mstate: an R Package for the Analysis of 
Competing Risks and Multi-State Models. J Stat Softw. 2011;38:1–30. 
doi: 10.1002/sim.2712
 33. Heymans MW, van Buuren S, Knol DL, van Mechelen W, de Vet HC. Variable 
selection under multiple imputation using the bootstrap in a prognostic 
study. BMC Med Res Methodol. 2007;7:33. doi: 10.1186/1471-2288-7-33
 34. Graham JW. Imputation in practice. In: Van Buuren S, ed. Flexible Imputa-
tion of Missing Data. Advanced Techniques Part 2. 2nd ed. Boca Raton, 
FL: CRC Press, Taylor & Francis Group; 2018.
 35. Wolbers M, Blanche P, Koller MT, Witteman JC, Gerds TA. Concordance 
for prognostic models with competing risks. Biostatistics. 2014;15:526–
539. doi: 10.1093/biostatistics/kxt059
 36. Trivedi A, Knight BP. ICD therapy for primary prevention in hypertrophic 
cardiomyopathy. Arrhythm Electrophysiol Rev. 2016;5:188–196. doi: 
10.15420/aer.2016:30:2
 37. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, Epstein AE, 
Almquist AK, Daubert JP, Lawrenz T, et al. Implantable cardioverter-defi-
brillators and prevention of sudden cardiac death in hypertrophic cardio-
myopathy. JAMA. 2007;298:405–412. doi: 10.1001/jama.298.4.405
 38. Maron BJ, Rowin EJ, Casey SA, Link MS, Lesser JR, Chan RHM, 
Garberich RF, Udelson JE, Maron MS. Hypertrophic cardiomyopathy in 
adulthood associated with low cardiovascular mortality with contempo-
rary management strategies. J Am Coll of Cardiol. 2015;65:1915–1928. 
doi: 10.1016/j.jacc.2015.02.061
 39. Javidgonbadi D, Andersson B, Abdon NJ, Schaufelberger M, Östman- 
Smith I. Factors influencing long-term heart failure mortality in patients 
with obstructive hypertrophic cardiomyopathy in Western Sweden: prob-
able dose-related protection from beta-blocker therapy. Open Heart. 
2019;6:e000963. doi: 10.1136/openhrt-2018-000963
 40. Mathew J, Zahavich L, Lafreniere-Roula M, Wilson J, George K, 
Benson L, Bowdin S, Mital S. Utility of genetics for risk stratification in pe-
diatric hypertrophic cardiomyopathy. Clin Genet. 2018;93:310–319. doi: 
10.1111/cge.13157
 41. Balaji S, DiLorenzo MP, Fish FA, Etheridge SP, Aziz PF, Russell MW, Tisma S, 
Pflaumer A, Sreeram N, Kubus P, et al. Risk factors for lethal arrhythmic 
events in children and adolescents with hypertrophic cardiomyopathy 
and an implantable defibrillator: an international multicenter study. Heart 
Rhythm. 2019;16:1462–1467. doi: 10.1016/j.hrthm.2019.04.040
 42. Bittencourt MI, Cader SA, Araújo DV, Salles ALF, Albuquerque FN, 
Spineti PPM, Albuquerque DC, Mourilhe-Rocha R. Role of myocardial 
fibrosis in hypertrophic cardiomyopathy: a systematic review and up-
dated meta-analysis of risk markers for sudden death. Arq Bras Cardiol. 
2019;112:281–289. doi: 10.5935/abc.20190045
 43. Alexander PMA, Nugent AW, Daubeney PEF, Lee KJ, Sleeper LA, Schuster T, 
Turner C, Davis AM, Semsarian C, Colan SD, et al. Long-term outcomes 
of hypertrophic cardiomyopathy diagnosed during childhood. Circulation. 
2018;138:29–36. doi: 10.1161/CIRCULATIONAHA.117.028895
 44. Noseworthy PA, Newton-Cheh C. Genetic determinants of sudden cardiac 
death. Circulation. 2008;118:1854–1863. doi: 10.1161/CIRCULATIONAHA. 
108.783654
 45. Kaski JP, Syrris P, Esteban MT, Jenkins S, Pantazis A, Deanfield JE, McKenna 
WJ, Elliott PM. Prevalence of sarcomere protein gene mutations in pre-
adolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc 
Genet. 2009;2:436–441. doi: 10.1161/CIRCGENETICS.108.821314
 46. Weissler-Snir A, Adler A, Williams L, Gruner C, Rakowski H. Prevention of 
sudden death in hypertrophic cardiomyopathy: bridging the gaps in knowl-
edge. Eur Heart J. 2017;38:1728–1737. doi: 10.1093/eurheartj/ehw268
D
ow
nloaded from
 http://ahajournals.org by on October 7, 2020
